CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450, ON June 15, 2005

Signature of Person Mailing this Document

DATÉ

Attorney Docket No. P31220X2C2R2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Leonard, et al.

Serial No.:

10/024,858

Group Art No.: Filed:

December 18, 2001

Customer No:

20462

1625

For:

PAROXETINE CONTROLLED RELEASE COMPOSITIONS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Information Disclosure Statement Under 37 C.F.R. §1.97(c)

The attached list of citations is being submitted under the provisions of 37 C.F.R. §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein, however, should not be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention.

The documents cited herein are listed on the enclosed PTO Form 1449. Copies of each are enclosed.

1 FC:1806

Serial No.: 10/024,858 Group Art Unit No.: 1625

This statement is being filed under the provisions of 37 C.F.R. §1.97(c), before the mailing date of a Final Office action or before the mailing date of a Notice of Allowance, along with authorization to charge the \$180.00 fee specified in 37 C.F.R. §1.17(p) to the Deposit Account No. 19-2570.

Please charge any additional fees under 37 C.F.R. §1.16 or §1.17 which may be required by this paper, or credit any overpayment, to the indicated Deposit Account.

Respectfully submitted,

Wayne J. Dustman
Attorney for Applicants
Registration No. 32,917

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5023
Facsimile (610) 270-5090
n:\wjd\paroxetine\p31220 paxil cr\ids leter based on c. rugg.doc

	NIN 5 G FRANCE		Sheet <u>1</u> of <u>1</u> .
Form PTO-1449	U. Department of Commerce	ATTY, DOCKET NO.	SERIAL NO.
	U.S Department of Commerce atent and Trademark Office	P31220X2C2R2	10/024,858
INFORMATION DISCLOSURE STATEMENT		APPLICANT	
	BY APPLICANT	Leonard, et al.	
		FILING DATE	GROUP
(Use several sheets if necessary)		December 18, 2001	1625

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	6, 168, 805	01/2001	Hein, et al.			
	5, 776, 969	07/1998	James			
	5, 668, 134	09/1997	Limstra, et al.			
	5, 811, 436	09/1998	Leonard, et al.			

FOREIGN PATENT DOCUMENTS

Document Number	Document Number Date Country			Subclass	Translation	
					Yes	No
 WO 95/20964	08/1995	WIPO				
WO 97/18798	05/1997	WIPO				
WO 91/13612	09/1991	WIPO				
0 714 663	06/1996	EP				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	OTTIET DOGGINE LET'S (Including Author, This, Date, Tertiment Tages, Etc.)
	Caley, et al., The Annals of Pharmacology, 1993, Vol. 27, pp. 1212-1222.
	FDA FOIA Materials, June 1993
	Lund, et al., Acta. Pharmacol. Toxicol., 1979, Vol. 44, pp. 289-295.
	Torii, et al., Naunyn-Schmiedeberg's Arch. Pharmacol., 1991, Vol. 344, pp. 564-567.
	Gale, J. of Pediatric Gast. and Nutrition, 1995, Vol. 21, Suppl. 1, pp. S22-S28.
	Bailey, et al., J. of Psychopharm., 1995, Vol. 9, No. 2, pp. 137-141.
	Finely, The Annals of Pharmacotherapy, 1994, Vol. 28, pp.1359-1369.
	J. van Harten, et al., Neuropsychopharmacology, 1994, Vol. 10, No. 35, pp. 104S.
EXAMINER	DATE CONSIDERED

·EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copyof this form with next communication to applicant.

n:\wjd\paroxetine\p31220 paxil cr\supp. 1449 based on c.rugg.doc